These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 585506)

  • 41. Inhibitors of dopamine inactivating systems as antiparkinson drugs.
    Youdim MB
    Adv Neurol; 1990; 53():483-8. PubMed ID: 2239488
    [No Abstract]   [Full Text] [Related]  

  • 42. [Local muscle reaction after injection of depot neuroleptics or antiparkinson drugs. Experimental study in rabbits with injection at the same injection site].
    Svendsen O
    Ugeskr Laeger; 1983 Aug; 145(35):2660-2. PubMed ID: 6137893
    [No Abstract]   [Full Text] [Related]  

  • 43. [The detection and separation of antiparkinson preparations in cadaveric material by gas-liquid chromatography].
    Vaĭnauskas PV
    Sud Med Ekspert; 1989; 32(3):43-5. PubMed ID: 2815218
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Preliminary clinical studies on the antiparkinson effects of 17-monochloroacetylajmaline].
    Errichiello G; Maglione S
    Minerva Med; 1974 May; 65(41):2357-9. PubMed ID: 4602984
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacological & biochemical characterization of antiparkinson drugs in reserpinized mice.
    David J; Kaul CL; Grewal RS
    Indian J Exp Biol; 1979 Aug; 17(8):760-4. PubMed ID: 575644
    [No Abstract]   [Full Text] [Related]  

  • 46. [Various kinds of antiparkinson agents and their characteristics].
    Nakatsuka A; Nomoto M
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1419-25. PubMed ID: 13677889
    [No Abstract]   [Full Text] [Related]  

  • 47. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
    Newman-Tancredi A; Cussac D; Audinot V; Nicolas JP; De Ceuninck F; Boutin JA; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):805-14. PubMed ID: 12388667
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [An evaluation of methods for isolating antiparkinson preparations from cadaveric material].
    Vaĭnauskas PV
    Sud Med Ekspert; 1990; 33(1):40-1. PubMed ID: 2336668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Advances in the research of anti-parkinson agents].
    Liu DK; Wu YL; Pan XP
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):240-5. PubMed ID: 3908019
    [No Abstract]   [Full Text] [Related]  

  • 50. [Antiparkinson medication: increasing effectiveness with piracetam].
    Finke J
    ZFA (Stuttgart); 1980 Jun; 56(17):1213-6. PubMed ID: 7424137
    [No Abstract]   [Full Text] [Related]  

  • 51. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
    Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
    Millan MJ; Maiofiss L; Cussac D; Audinot V; Boutin JA; Newman-Tancredi A
    J Pharmacol Exp Ther; 2002 Nov; 303(2):791-804. PubMed ID: 12388666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Anticholinergic anti-Parkinson agents].
    Taurand S
    Soins; 1996 Apr; (605):61-2. PubMed ID: 8716255
    [No Abstract]   [Full Text] [Related]  

  • 54. Old versus new antiparkinsonian agents?
    Reynolds NC
    Wis Med J; 1985 Oct; 84(10):20-2. PubMed ID: 4072238
    [No Abstract]   [Full Text] [Related]  

  • 55. Patterns of antipsychotic drug use in four Southeastern state hospitals.
    Mason AS; Nerviano V; DeBurger RA
    Dis Nerv Syst; 1977 Jul; 38(7):541-5. PubMed ID: 17517
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Tranquilizing agents: extrapyramidal and antiparkinsonism activities].
    Bordeleau JM; Tétreault L; Elie R
    Vie Med Can Fr; 1972 Feb; 1(2):118-26. PubMed ID: 4637390
    [No Abstract]   [Full Text] [Related]  

  • 57. [Parkinson therapy. New agents in the medical treatment of Parkinson disease].
    Ulm G
    Med Monatsschr Pharm; 1987 Oct; 10(10):304-7. PubMed ID: 3316955
    [No Abstract]   [Full Text] [Related]  

  • 58. [Metabolism of antiparkinson drugs. An example of competitive hydroxylation].
    Stock B; Spiteller G
    Arzneimittelforschung; 1979; 29(4):610-5. PubMed ID: 582755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Influencing of the subnarcotic and cholinergically potentiated action of barbital through antiparkinson drugs in mice].
    Oelszner W; Westermann KH; Eger J
    Acta Biol Med Ger; 1971; 27(5):993-9. PubMed ID: 5148782
    [No Abstract]   [Full Text] [Related]  

  • 60. [Misuse of anticholinergic agents with central effects].
    Alvăn G; Nordin C; Rydberg U
    Lakartidningen; 1982 Oct; 79(42):3834-5. PubMed ID: 7154760
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.